Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Obesity’s Effects on Inflammatory Markers in Patients with RA

Arthritis Care & Research  |  November 29, 2017

New research has examined the effect of obesity on inflammatory markers, specifically C-reactive protein (CRP) level and erythrocyte sedimentation rate, in patients with rheumatoid arthritis (RA). Researchers found higher BMIs were associated with higher CRP levels in women both with and without RA, suggesting the phenomenon is related to adiposity and not an indication of disease activity. For men with RA, low BMI was associated with higher CRP levels, which proved to be RA-specific but not a direct causal effect of adiposity…

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

Michele B. Kaufman, PharmD, BCGP  |  November 29, 2017

Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…

SIRT1: A Therapeutic Target for Osteoporosis?

Lara C. Pullen, PhD  |  November 27, 2017

New research has found the sirtuin family of proteins may be a positive regulator of bone mass. In the study, pharmacological activation of SIRT1 in mice resulted in increased bone mass, suggesting the pharmacological activation of SIRT1 may protect against osteoporosis…

Bisphosphonate Drug Holiday & Hip Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  November 21, 2017

New research found women on bisphosphonate therapy who take a drug holiday experience a higher rate of hip fracture…

Year in Review: Expert Covers 2017’s Key Clinical Findings

Thomas R. Collins  |  November 20, 2017

In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Psoriasis Tied to Higher Risk of Serious Liver Disease

Lisa Rapaport  |  November 13, 2017

(Reuters Health)—People with chronic inflammatory disorders, such as psoriasis and rheumatoid arthritis (RA), may have an increased risk of developing serious liver damage, a recent study suggests. These inflammatory disorders are often treated with methotrexate, a medication linked to an increased risk of liver disease. For the current study, researchers followed more than 1 million…

Eat to Fight Inflammation & Promote Weight Loss

Karen Appold  |  November 11, 2017

Managing weight loss through diet may help patients with rheumatic disease reduce inflammation. Here are some strategies on weight loss and eating for rheumatologists and patients…

Heated Gloves Provide Relief from Hand Pain, Dysfunction in Diffuse Systemic Sclerosis

Rosemarie A. Curley, MPT, DPT  |  November 10, 2017

Raynaud’s phenomenon in scleroderma or systemic sclerosis (SSc) is associated with significant discomfort and functional disability, especially in the presence of digital ulcers.1 Having lived with diffuse systemic sclerosis (dSSc) for nearly a decade, I can attest to this. It has been my experience that the hand pain and dysfunction in dSSc stems from Raynaud’s…

Rheumatology Case Report: TINU Syndrome with Concomitant Synovitis

Ambreesh Chawla, MD, David Benderson, MD, Mikhail Kotlov, MD, Evan Leibowitz, MD, & Ashraf Raslan, MD  |  November 10, 2017

Tubulointerstitial nephritis and uveitis (TINU) syndrome, also known as Dobrin syndrome, is a rare oculo-renal inflammatory disease. It was first described in 1975 by American physician Robert Dobrin, MD.1 It manifests as acute interstitial nephritis and bilateral uveitis. In addition, patients often experience nonspecific systemic findings, such as fever, weight loss, malaise, myalgia and arthralgia. TINU…

Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  November 9, 2017

Medications for serious or life-threatening conditions may receive accelerated approval from the U.S. Food and Drug Administration (FDA) by showing an effect on surrogate measures that are reasonably likely to predict a treatment’s clinical benefit. Post-approval confirmatory drug trials are then required to determine whether or not these effects translate into clinical improvements. In recent…

  • « Previous Page
  • 1
  • …
  • 175
  • 176
  • 177
  • 178
  • 179
  • …
  • 344
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences